Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Blanco-Prieto, M.J. (María José) | - |
dc.creator | Besseghir, K. (Kamel) | - |
dc.creator | Zerbe, O. (Oliver) | - |
dc.creator | Andris, D. (Dani) | - |
dc.creator | Orsolini, P. (Piero) | - |
dc.creator | Heimgartner, F. (Fréderic) | - |
dc.creator | Merkle, H.P. (Hans P.) | - |
dc.creator | Gander, B. (Bruno) | - |
dc.date.accessioned | 2012-05-31T09:42:27Z | - |
dc.date.available | 2012-05-31T09:42:27Z | - |
dc.date.issued | 2000-06 | - |
dc.identifier.citation | Blanco-Prieto MJ, Besseghir K, Zerbe O, Andris D, Orsolini P, Heimgartner F, et al. In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres. J Control Release 2000 Jun 15;67(1):19-28. | es_ES |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://hdl.handle.net/10171/22375 | - |
dc.description.abstract | The purpose of this study was to design poly(lactide-co-glycolide) (PLGA) microspheres for the continuous delivery of the somatostatin analogue, vapreotide, over 2–4 weeks. The microspheres were produced by spray-drying and the desired characteristics, i.e. high encapsulation efficiency and controlled release over 2–4 weeks, achieved through optimizing the type of polymer, processing solvent, and co-encapsulated additive. The in vitro release was tested in fetal bovine serum preserved with 0.02% of thiomersal. Furthermore, formulations were injected intramuscularly into rats to obtain pharmacokinetic profiles. Encapsulation efficiency was between 34 and 91%, depending on the particular formulation. The initial peptide release (within 6 h) was lowest, i.e. <20%, when acetic acid was used as processing solvent and highest, i.e. 57%, with dichloromethane. The various co-encapsulated additives generally lowered the encapsulation efficiency by 15–30%. The best formulation in terms of low burst and effective drug serum levels (>1 ng/ml) over 21–28 days in rats was the one made with end-group uncapped PLGA 50:50, the solvent acetic acid and the additive polyethyleneglycol. In conclusion, the optimization of formulation parameters allowed us to produce vapreotide-loaded PLGA microspheres of suitable characteristics for therapeutic use. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Somatostatin analogue | es_ES |
dc.subject | Microspheres | es_ES |
dc.subject | Release kinetics | es_ES |
dc.subject | PLA/PLGA | es_ES |
dc.subject | Plasma levels | es_ES |
dc.title | In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://www.sciencedirect.com/science/article/pii/S0168365999002898 | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.